



Better planning of your BE studies for Long-acting Antipsychotic Injections

Long-acting injections (LAIs) of antipsychotic medication (depots) are being developed specifically to promote treatment adherence and are a valuable option **for maintenance medication in psychotic illnesses**. With a competent team of **250 experienced scientists** and a **stern focus on providing quality solutions**, Veeda is well equipped to meet the special clinical trial execution requirements for generic drug development of **Long-acting injections (LAIs) of antipsychotics**.



Main challenges for LAI antipsychotics

- 1 **Designing the studies** in line with various regulatory requirements.
- 2 Getting the **stabilized schizophrenic patients** with tolerability assessment.
- 3 Handling of **BENOC** for executing the trial.
- 4 **Patient retention** due to long duration of the trial.

Few LAI antipsychotics requiring BE studies are

- Aripiprazole depot injection
- Olanzapine modified release injection
- Paliperidone palmitate modified release injection
- Risperidone modified release injection
- Leuprolide acetate injection

Our Capabilities

- Team having experience in understanding the **challenges of study design and logistics of study execution**.
- Consultant Psychiatrist as a key opinion leader, **with over 10 years of clinical trial experience** and having successfully faced 3 US FDA inspections.
- **Investigators database** having prior experience in handling schizophrenic patients.
- Investigators' sites inspected by USFDA.
- Excellent regulatory liaison with proven track record.

Veeda Advantage

100% data review by Quality Assurance

Privately owned Clinical Research Organization without association with any Pharma Company

Road Map for **more than 25 molecules for Patient based Pharmacokinetic Studies** and **more than 15 molecules for Clinical End Point Studies**

[CLICK HERE TO KNOW MORE](#)

Proven regulatory track record with **8 USFDA, 4 European, 4 WHO & 7 ANVISA** audits

Trusted CRO partner to 10 of the world's top 15 Global Pharmaceutical Companies

State of the art Bio-analytical Unit with more than 340 validated assays in its library of compounds, **35 NCE methods** and **20 more under development**.